<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6543">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902303</url>
  </required_header>
  <id_info>
    <org_study_id>BTL - 2013-06-0161</org_study_id>
    <secondary_id>HTR - 13-131178</secondary_id>
    <nct_id>NCT01902303</nct_id>
  </id_info>
  <brief_title>Evaluation of Cold Sore Treatments on UV Induced Cold Sores</brief_title>
  <official_title>Evaluation of Cold Sore Treatments on UV Induced Cold Sores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beech Tree Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cliantha Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwich Clinical Research Associates Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beech Tree Labs, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a new drug treatment is effective to block the
      development of a cold sore lesion following Ultra Violet (UV)  exposure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Block the symptomatic sequence of a lesion of oral herpes simplex outbreak</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual examination of cold sores by trained evaluator and subject self assessment after exposure to UV.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Oral Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTL-TML-HSV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Sublingual micro dosing of placebo for 7 days</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTL-TML-HSV</intervention_name>
    <description>Sublingual micro dosing of BTL-TML-HSV for 7 days</description>
    <arm_group_label>BTL-TML-HSV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history of recurrent cold sores averaging 2 or more episodes per year

          -  UV exposure is known to cause a cold sore outbreak

        Exclusion Criteria:

          -  History of abnormal reactions to sunlight

          -  Used antiviral therapy directly prior to entering study

          -  Any other condition which in the opinion of the Investigator may affect the results
             or place the subject at undue risk.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McMichael, PhD</last_name>
    <role>Study Director</role>
    <affiliation>President, Beech Tree Labs, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hill Top Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Henderson</last_name>
      <phone>727-498-3804</phone>
      <email>phenderson@hill-top.com</email>
    </contact>
    <investigator>
      <last_name>John V. Murray, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hill Top Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hill Top Research, Incorporated</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3L-2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsie Kohoot</last_name>
      <phone>204-453-1835</phone>
      <phone_ext>229</phone_ext>
      <email>ekohoot@hill-top.com</email>
    </contact>
    <contact_backup>
      <last_name>Joelle Potrebka</last_name>
      <phone>204-453-1835</phone>
      <phone_ext>239</phone_ext>
      <email>jpotrebka@hill-top.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Chernish, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Labialis</keyword>
  <keyword>Herpes Simplex</keyword>
  <keyword>Herpes</keyword>
  <keyword>Ultra Violet (UV) Induced</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Labialis</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Stomatitis, Herpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
